Accuracy of the ICAGEN-Targeta progesterone enzyme-linked immunosorbent assay (ELISA) test kit to measure plasma progesterone was compared to that of radioimmunoassay (RIA) in 166 canine samples. Overall agreement of ICAGEN-Target ELISA and RIA was 85% (141/166). Agreement of ELISA and RIA at high (5 ng/ml or greater), medium (greater than 1 ng/ml, less than 5 ng/ml), and low (0 to 1 ng/ml) plasma progesterone concentrations was 96% (72/75), 73% (19/26), and 77% (50/65), respectively. Use of whole blood resulted in unreliable progesterone concentration results by ELISA when compared to plasma progesterone concentrations measured by RIA (n = 140). Use of this ELISA test kit to determine canine ovulation date should start within three to four days after onset of proestrus and continue every other day until the first detection of medium concentrations (greater than 1 ng/ml, less than 5 ng/ml). Daily plasma testing during the time of transition from medium to high (5 ng/ml or greater) concentrations was essential for determining ovulation date. The second or third day after the first appearance of high plasma progesterone concentrations using this kit should be the day of breeding for optimal reproductive performance.
Skip Nav Destination
Article navigation
1 January 1995
Research Article|
January 01 1995
Evaluation of the ICAGEN-Target canine ovulation timing diagnostic test in detecting canine plasma progesterone concentrations
J Am Anim Hosp Assoc (1995) 31 (1): 57–64.
Citation
K Manothaiudom, SD Johnston, RL Hegstad, SK Hardy; Evaluation of the ICAGEN-Target canine ovulation timing diagnostic test in detecting canine plasma progesterone concentrations. J Am Anim Hosp Assoc 1 January 1995; 31 (1): 57–64. doi: https://doi.org/10.5326/15473317-31-1-57
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Sign in via your Institution
Sign in via your InstitutionCiting articles via
Utility of Spleen and Liver Cytology in Staging of Canine Mast Cell Tumors
Megan Brown, DVM, MS, DACVIM (Oncology), Jessica Hokamp, DVM, PhD, DACVP, Laura E. Selmic, BVM, MPH, DACVS (Small Animal), DECVS, Rachel Kovac, DVM, MS, DACVIM (Oncology)
Complete Blood Counts and Blood Smear Analyses in 312 Diabetic Dogs (2007–2017)
Tanner S. Slead, DVM, Andrew D. Woolcock, DVM, DACVIM, J. Catharine Scott-Moncrieff, VetMB, MA, MS, Joanne B. Messick, VMD, PhD, George E. Moore, DVM, PhD
Feline Emphysematous Gastritis in a Cat with Pancreatitis and Secondary Hepatic Lipidosis
Emily Fulton, BVSc, Gawain Hammond, MA, VetMB, MVM, CertVDI, DECVDI, FHEA, Francesco Marchesi, DVM, PhD, DECVP, Marta Hernández Pérez, DVM, Alison E. Ridyard, BVSc, DSAM, DECVIM-CA
Outcome of Localized Bile Duct Carcinoma in Six Dogs Treated with Liver Lobectomy
Atsushi Maeda, DVM, Sho Goto, DVM, Ryota Iwasaki, DVM, PhD, Koji Yamada, DVM, Mami Murakami, DVM, PhD, Hiroki Sakai, DVM, PhD, Takashi Mori, DVM, PhD
Mediastinal Serous Cavity Mesothelioma in Two Dogs
Sean P. McDonough, DVM, Peter V. Scrivani, DVM, Karine Gendron, DVM, May Tse, DVM